PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells

Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses

(2012) W. E. Pierceall et al.   ANNALS OF ONCOLOGY

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors

(2011) Victoria E. Anderson et al.   CANCER RESEARCH

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

(2011) S. Kummar et al.   CANCER RESEARCH

MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers

(2011) E. Vilar et al.   CANCER RESEARCH

PARP Inhibitor Treatment in Ovarian and Breast Cancer

(2011) Marcie K. Weil et al.   CURRENT PROBLEMS IN CANCER

The knock-down of ERCC1 but not of XPF causes multinucleation

(2011) Julie Rageul et al.   DNA REPAIR

PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer

(2011) Ian Paul et al.   JOURNAL OF PATHOLOGY

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

(2011) Neil Johnson et al.   NATURE MEDICINE

Iniparib in Metastatic Triple-Negative Breast Cancer

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Drug Inhibition Profile Prediction for NFκB Pathway in Multiple Myeloma

(2011) Huiming Peng et al.   PLoS One

Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells

(2010) Zhenfeng Zhang et al.   CARCINOGENESIS

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer

(2010) David R. Gandara et al.   Journal of Thoracic Oncology

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis

(2010) Sufeng Chen et al.   LUNG CANCER

Photoaffinity Labeling Reveals Nuclear Proteins That Uniquely Recognize Cisplatin−DNA Interstrand Cross-Links

(2009) Guangyu Zhu et al.   BIOCHEMISTRY

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination

(2009) Helen E Bryant et al.   EMBO JOURNAL

The XPA-binding domain of ERCC1 Is Required for Nucleotide Excision Repair but Not Other DNA Repair Pathways

(2009) Barbara Orelli et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cisplatin sensitivity is related to late DNA damage processing and checkpoint control rather than to the early DNA damage response

(2009) Anamaria Brozovic et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links

(2009) A. Z. Al-Minawi et al.   NUCLEIC ACIDS RESEARCH

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression

(2009) Rafael Rosell et al.   PLoS One

Platinum Resistance: The Role of DNA Repair Pathways

(2008) L. P. Martin et al.   CLINICAL CANCER RESEARCH

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

(2008) B. Evers et al.   CLINICAL CANCER RESEARCH

BRCA1: A New Genomic Marker for Non–Small-Cell Lung Cancer

(2008) Noemí Reguart et al.   Clinical Lung Cancer

A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity

(2008) Christopher J. Lord et al.   DNA REPAIR

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

Preclinicalversusclinical drug combination studies

(2008) Ting-Chao Chou   LEUKEMIA & LYMPHOMA

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA